Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25

Canaccord biotech analyst to hold a dinner meeting

In conjunction with the 58th Annual ASH Meeting, Biotech Analyst Newman hosts a Key Opinion Leader Dinner Meeting with Jae Park, MD, who discusses the implications for Juno Therapeutics (JUNO), Kite Pharma (KITE), bluebird bio (BLUE) and Novartis (NVS), on December 3 at 10 pm.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$20.43

0.53 (2.66%)

12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.
11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
KITE Kite Pharma
$50.76

0.04 (0.08%)

11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
BLUE bluebird bio
$69.75

1.1 (1.60%)

12/01/16
PIPR
12/01/16
NO CHANGE
PIPR
Overweight
bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/02/16
MAXM
12/02/16
NO CHANGE
Target $87
MAXM
Buy
bluebird bio price target raised to $87 from $57 at Maxim
Maxim analyst Jason McCarthy said the early data on bluebird bio's bb2121 show it is inducing clinical responses, including complete responses, "essentially in the absence of" CRS and neuro-toxicity. While waiting to see if this trend continues, given the positive bb2121 data so far in multiple myeloma, McCarthy raised his price target on bluebird shares to $87 from $57. He keeps a Buy rating on the stock, noting that he is now factoring in a bb2121 launch in 2021.
NVS Novartis
$68.17

0.42 (0.62%)

11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

UTX

United Technologies

$112.09

-0.57 (-0.51%)

18:32
02/23/17
02/23
18:32
02/23/17
18:32
Hot Stocks
Carrier expands air conditioner, heat pump recall »

United Technologies'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

, BUD

AB InBev

$108.76

-0.4 (-0.37%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Craft Brew reschedules Q4 report to allow additional time for audit »

Craft Brew Alliance…

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

BUD

AB InBev

$108.76

-0.4 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLPG

Galapagos NV

$69.96

0.3 (0.43%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Galapagos doses first healthy volunteer with CF combo GLPG2222, GLPG2451 »

Galapagos announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RH

Restoration Hardware

$25.19

-0.82 (-3.15%)

, SENS

Senseonics

18:15
02/23/17
02/23
18:15
02/23/17
18:15
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: RH…

RH

Restoration Hardware

$25.19

-0.82 (-3.15%)

SENS

Senseonics

OLED

Universal Display

$67.45

-3.8 (-5.33%)

JWN

Nordstrom

$43.94

-1.41 (-3.11%)

EBS

Emergent BioSolutions

$29.78

-0.14 (-0.47%)

STMP

Stamps.com

$133.75

-0.7 (-0.52%)

MELI

MercadoLibre

$199.82

-0.59 (-0.29%)

BIDU

Baidu

$184.64

-1.37 (-0.74%)

HLF

Herbalife

$59.40

-1.34 (-2.21%)

GPS

Gap

$23.97

-0.9 (-3.62%)

AXDX

Accelerate Diagnostics

$24.75

0.3 (1.23%)

INCY

Incyte

$121.95

0.59 (0.49%)

DDS

Dillard's

$54.68

-0.56 (-1.01%)

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

CXW

CoreCivic

$34.00

-0.5 (-1.45%)

GEO

Geo Group

$47.37

-0.38 (-0.80%)

SRPT

Sarepta

$30.15

-0.23 (-0.76%)

ACIA

Acacia Communications

$63.43

1.21 (1.94%)

ZOES

Zoe's Kitchen

$22.46

-0.34 (-1.49%)

ACHC

Acadia

$43.24

0.6 (1.41%)

BGS

B&G Foods

$46.90

-0.65 (-1.37%)

SPLK

Splunk

$64.90

-0.08 (-0.12%)

HPE

HP Enterprise

$24.66

-0.12 (-0.48%)

ACHN

Achillion

$4.24

0.04 (0.95%)

PFGC

Performance Food Group

$24.35

0.4 (1.67%)

NAO

Nordic American Offshore

$2.05

-0.05 (-2.38%)

CELG

Celgene

$119.46

0.19 (0.16%)

HCLP

Hi-Crush Partners

$20.55

-1.4 (-6.38%)

SWN

Southwestern Energy

$8.35

-0.22 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 03

    Mar

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    Apr

  • 05

    Apr

  • 19

    Apr

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

COF

Capital One

$93.41

0.52 (0.56%)

18:11
02/23/17
02/23
18:11
02/23/17
18:11
Hot Stocks
Capital One: DOJ, Treasury, New York probing anti-money laundering program »

Capital One disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

XOM

Exxon Mobil

$81.78

0.85 (1.05%)

18:07
02/23/17
02/23
18:07
02/23/17
18:07
Hot Stocks
New Exxon Mobil CEO: 'Climate risks warrant action' »

New Exxon Mobil CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNT

Alliant Energy

$39.11

0.46 (1.19%)

18:04
02/23/17
02/23
18:04
02/23/17
18:04
Earnings
Alliant Energy sees FY17 EPS $1.92-$2.06, consensus $2.00 

Sees FY17 CapEx $1.4B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

LNT

Alliant Energy

$39.11

0.46 (1.19%)

18:02
02/23/17
02/23
18:02
02/23/17
18:02
Earnings
Alliant Energy reports Q4 EPS 28c, consensus 28c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

STZ

Constellation Brands

$153.60

-6.6 (-4.12%)

17:57
02/23/17
02/23
17:57
02/23/17
17:57
Hot Stocks
Constellation Brands says 'ready to act' in any border tax situation »

Sees over $1B in free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

, CLC

Clarcor

$82.96

-0.02 (-0.02%)

17:53
02/23/17
02/23
17:53
02/23/17
17:53
Hot Stocks
CyrusOne to replace Clarcor in S&P 400 as of 3/1 open »

S&P 500 constituent…

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

CLC

Clarcor

$82.96

-0.02 (-0.02%)

PH

Parker-Hannifin

$153.70

-2.16 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 06

    Mar

DDS

Dillard's

$54.68

-0.56 (-1.01%)

, ISIL

Intersil

17:52
02/23/17
02/23
17:52
02/23/17
17:52
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$54.68

-0.56 (-1.01%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

, EQY

Equity One

$31.91

0.39 (1.24%)

17:50
02/23/17
02/23
17:50
02/23/17
17:50
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ENDP

Endo

$13.39

0.5 (3.88%)

, REG

Regency Centers

$70.95

0.94 (1.34%)

17:49
02/23/17
02/23
17:49
02/23/17
17:49
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.39

0.5 (3.88%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 13

    Mar

  • 14

    Mar

REG

Regency Centers

$70.95

0.94 (1.34%)

, ENDP

Endo

$13.39

0.5 (3.88%)

17:48
02/23/17
02/23
17:48
02/23/17
17:48
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$70.95

0.94 (1.34%)

ENDP

Endo

$13.39

0.5 (3.88%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 28

    Feb

  • 13

    Mar

  • 14

    Mar

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

, CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

17:46
02/23/17
02/23
17:46
02/23/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Pitney Bowes, CBOE Holdings »

Pitney Bowes to replace…

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

, PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

17:45
02/23/17
02/23
17:45
02/23/17
17:45
Hot Stocks
CBOE Holdings to repplace Pitney Bowes in S&P 500 as of 3/1 open »

CBOE (CBOE) is acquiring…

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

BATS

Bats Global Markets

$35.65

-0.08 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INCY

Incyte

$121.95

0.59 (0.49%)

, SE

Spectra Energy

$41.00

-0.31 (-0.75%)

17:42
02/23/17
02/23
17:42
02/23/17
17:42
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$121.95

0.59 (0.49%)

SE

Spectra Energy

$41.00

-0.31 (-0.75%)

ENB

Enbridge

$41.71

-0.44 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

STMP

Stamps.com

$133.75

-0.7 (-0.52%)

17:41
02/23/17
02/23
17:41
02/23/17
17:41
Earnings
Stamps.com reports Q4 EPS $2.73, consensus $2.36 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$121.95

0.59 (0.49%)

, CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

17:39
02/23/17
02/23
17:39
02/23/17
17:39
Hot Stocks
Breaking Hot Stocks news story on Incyte, CBOE Holdings, Regency Centers »

Incyte, CBOE Holdings,…

INCY

Incyte

$121.95

0.59 (0.49%)

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:36
02/23/17
02/23
17:36
02/23/17
17:36
Earnings
MasTec sees Q1 adjusted EPS 51c, consensus 23c »

Sees Q1 revenue $1.05B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:36
02/23/17
02/23
17:36
02/23/17
17:36
Earnings
MasTec sees FY17 adjusted EPS $2.35, consensus $2.09 »

Sees FY17 revenue $5.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

GOOG

Alphabet

$831.33

0.57 (0.07%)

, GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

17:35
02/23/17
02/23
17:35
02/23/17
17:35
Periodicals
Breaking Periodicals news story on Alphabet, Alphabet Class A »

Alphabet's Waymo…

GOOG

Alphabet

$831.33

0.57 (0.07%)

GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
MasTec reports Q4 adjusted EPS 70c, consensus 54c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SSRI

Silver Standard

$10.90

-0.06 (-0.55%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
Silver Standard reports Q4 adjusted EPS 26c, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ALJ

Alon USA Energy

$11.73

0.17 (1.47%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
Alon USA Energy reports Q4 EPS ex-items (20c), consensus (33c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.